Acute toxicity of conformal high dose interstitial brachytherapy boost in prostate cancer

Neoplasma

Volumn 53, Issue 5, 2006, Pages 410-417

  Soumarova R ^a   Homola, L ^a   Stursa M ^b   Perkova H ^a  

^a JG Mendel Cancer Centre   (Czech Republic)

^b Hospital Novy Jicin   (Czech Republic)

Author keywords

Acute toxicity; High dose rate interstitial brachytherapy; Organ confined prostate cancer

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DOSIMETRY; DRUG MEGADOSE; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEMATURIA; HORMONAL THERAPY; HUMAN; INTERSTITIAL RADIATION; MALE; MORBIDITY; NAUSEA; NOCTURIA; PAIN; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RECTUM DISEASE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; THROMBOSIS; URINARY URGENCY; URINE RETENTION; UROGENITAL TRACT DISEASE; VOMITING;

EID: 33750610464     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. MARTINEZ AA. [abstr]. ASTRO teaching course, 1999.
2. VICINI FA, MARTINEZ AA, HANKS G et al. An interinstitutional and interspeciality comparison of prostate cancer treatment outcome data based upon predefined pro categories and minimum follow-up. Cancer 2002; 95: 2126-2135.
3. HUDSON R. Brachytherapy treatments increasing among Medicare population. Health policy Brief of the American Urologie Association, Inc. 1999; 9: 1-8.
4. HANKS GE, MARTZ KL, DIAMOND JJ. The effect of dose on local control of the prostatic cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299-1305.
5. MARTINEZ AA, GUSTAFSON G, GONZALEZ J et al. Dose escalation using conformai high dose rate brachytherapy improves outcome in unfavourable prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 316-327.
6. CRITZ FA, WILLIAMS K, SORACE R et al. Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques. Urology 2000; 164: 738-743.
7. GHALY M, WALLNER K, MERRICK G et al. Brachytherapy versus brachytherapy and external beam radiation for prostate cancer: morbidity outcomes from two prospective randomized multicenter trials [abstr]. Program and abstracts of the American Society for Therapeutic Radiology and Oncology 44th Annual Meeting 2002.
8. GRILLS IS, MARTINEZ AA, HOLLANDER M et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004; 171: 1098-1104.
9. BORGHEDE G, NEFELIN H, HOLMANG S et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 1997; 44: 237-244.
10. KOVÁCS G, WIRTH B, BERTERMANN H et al. Prostate preservation by combined external beam and HDR brachytherapy of nodal negative prostate cancer patients: An intermediate analysis after 10 years experience (Abstr). Int J Radiat Oncol Biol Phys 1996; 36 Suppl 1: 198
11. BRENNER DJ, HALL EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095-1101.
12. VIGNEAULT E, BEAULIEU L, AUBIN S et al. Int J Radiat Oncol Biol Phys 2001; 51 Suppl 1: 317-318.
13. LACHANCEB, BÉLIVEAU-NADEAU D, LESSARD Éet al. Early clinical experience with anatomy-based inverse planning dose optimization for high-dose-rate boost of the prostate. Int J Radiat Oncol Biol Phys 2002; 54: 86-100.
14. COX JD, STETZ J, PAJAK TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
15. POLLACK A, SMITH LG, VON ESCHENBACH AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 2000; 48(2): 507-512.
16. FIVEASH JB, HANKS G, ROACH M et al. 3D conformal radiation therapy for high-grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 2000; 47: 335-342.
17. KUBAN D, POLLACK A, HUANG E et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57(5): 1260-1268.
18. KUPELIAN PA, MOHAN DS, LYONS J et al. Higher than standard radiation dose (≥72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 567-574.
19. POLLACK A, ZAGARS GK, STARSCHALL G et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-1105.
20. ZELEFSKY MJ, LEIBEL SA, GAUDIN PB et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41(3): 491-500.
21. HANKS GE, SCHULTHEISS TE, HALON AL et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997; 37(3): 543-550.
22. FOWLER J, CHAPPELL R, RITTER M. Is α/β for prostate tumours really low? Int J Radiat Oncol Biol Phys 2001; 50: 1021-1031.
23. RUBIN MA, BAGIELLA E, ENNIS RD. Urethral sparing techniques in prostate brachytherapy and cryosurgery: is cancer also being spared [abstr]. Program and abstracts of the American Society for Therapeutic Radiology and Oncology 44th Annual Meeting: 2002.
24. ALLEN ZA, MERRICK GS, HITLER WM et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 2005; 62: 981-987.
25. LOCKE J, ELLIS W, WALLNER K et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 712-719.
26. SCHWARZ DJ, SCILD SE, WONG WW et al. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 61: 60-63.
27. DESAI J, STOCK RG, STONE NN et al. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 1998; 6: 135-141.
28. SCHWARZ DJ, SCILD SE, WONG WW et al. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 61: 60-63.
29. GELBLUM DY, POTTERS L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000; 48: 119-124.
30. KANG SK, CHOU RH, DODGE RK et al. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 53: 99-103.
31. BOLLA M, GONZALEZ D, WARDE P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
32. YOSHIOKA Y, NOSE T, YOSHIDA K et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 2003; 56: 213-220.
33. PELLIZZON ACA, NADALI W, SALVAJOLI JV et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiotherapy and Oncology 2003; 66: 167-172.